Mathew Gerving, MD
Internal Medicine · Fargo, NDNPI 1285243543
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $696 and has fallen 54.6% since, to $316 in 2025.
Across 72 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$242
- Pfizer$227
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$142
- Lundbeck LLC$115
- Boehringer Ingelheim$64
- GSK$50
- plus $335 from 12 others
What the payments were for
- Food & beverage$1,175100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 14 | $242 |
| Pfizer | 17 | $227 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $142 |
| Lundbeck LLC | 7 | $115 |
| Boehringer Ingelheim | 4 | $64 |
| GSK | 3 | $50 |
| Novartis | 3 | $44 |
| Bayer | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Neurocrine Biosciences, Inc. | 2 | $33 |
| Exact Sciences | 2 | $31 |
| AbbVie | 2 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Verona Pharma, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$1,175 in reported general payments places this provider in the 85th percentile of 159 internal medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $60,919 |
| MounjaroTirzepatide | 34 | $46,778 |
| JardianceEmpagliflozin | 43 | $41,258 |
| TrulicityDulaglutide | 31 | $36,861 |
| OzempicSemaglutide | 15 | $23,948 |
| FarxigaDapagliflozin Propanediol | 20 | $15,596 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,696 |
| NexletolBempedoic Acid | 17 | $8,751 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $6,730 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,843 |
| Baclofen | 14 | $1,648 |
| Levothyroxine Sodium | 134 | $1,488 |
| Rosuvastatin Calcium | 135 | $1,448 |
| Metoprolol Succinate | 97 | $1,413 |
| Tamsulosin Hcl | 88 | $1,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $227 | $60,91972 claims |
| Boehringer IngelheimJardiance | $64 | $41,25843 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $15 | $25,29234 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $18 | $15,48130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 159 internal medicine providers in North Dakota.
Other internal medicine in Fargo
- Michael LillestolFargo$18K
- Brent HellaFargo$3K
- Tricia LangloisFargo$2K
- Mark YoheFargo$2K
- Dalton PeasleeFargo$2K
- Anya de LeeuwFargo$1K
- Anastasia SchroederFargo$1K
- Aselo LayawenFargo$1K
- Guillermo EstradaFargo$1K
- Sai Anil Kumar SriramojuFargo$604
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.